

Meningeal barrier breakdown and local immune response during neonatal bacterial meningitis

Sol (Sophia) Kim¹, Luke Joyce², Brady Spencer², Julia Derk¹, Kelly Doran², Julie Siegenthaler¹

¹Department of Pediatrics, Section of Developmental Biology, University of Colorado Anschutz Medical Campus, Aurora, CO

²Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO



OBJECTIVES


- Developing a neonatal bacterial meningitis model to study the functional role and response of the arachnoid barrier in CNS diseases.
- Investigating how leptomeningeal border-associated macrophages respond to infection and alter the arachnoid barrier integrity.

INTRODUCTION


- The central nervous system (CNS) is protected by several types of barriers, one of which is blood-cerebrospinal fluid barrier (B-CSFB).
- One component of the B-CSFB is the arachnoid barrier (AB), the outer arachnoid layer that consists of epithelial-like cells connected by extensive junctional proteins (E-cadherin/Claudin-11) and regulates cellular and molecular movement between the CSF and the periphery.
- Streptococcus agalactiae* (Group B *Streptococcus*, GBS) is the leading cause of life-threatening meningitis in newborns and can lead to long-term neurological deficits in children who survive the initial infection during infancy.
- In the absence of AB prenatally, a significantly higher burden of GBS has been observed in the leptomeninges.
- Border-associated macrophages (BAMs) (CD206⁺/LYVE-1⁺) are among the most abundant resident immune cells in the meninges. Upon inflammation, BAMs become phagocytic and express inflammatory cytokines.
- Current gaps in the field include: 1) *Is the AB functionally perturbed in bacterial meningitis and what are the cellular and molecular mechanisms driving AB breakdown?*, and 2) *How do meningeal BAMs respond to GBS infection and do they contribute to the altered AB in diseased-state?*

METHODS


A. Acute Neonatal GBS Infection Model and Sample Collection




B. Histological Analysis of Arachnoid Barrier Post-Infection




C. Tracer Dye-Based Arachnoid Barrier Integrity Assay (ABIA)




ARACHNOID BARRIER JUNCTIONAL PROTEIN MISLOCALIZATION POST-INFECTION



LOSS OF ARACHNOID BARRIER INTEGRITY FOLLOWING GBS INFECTION



ALTERED LEPTOMENINGEAL BAM MORPHOLOGY AND LYVE-1 EXPRESSION POST-INFECTION



CONCLUSIONS

- We developed a neonatal bacterial meningitis model using GBS to study the acute response at the B-CSFB, specifically the arachnoid barrier (AB).
- Infection with GBS did not alter the expression level of AB junctional proteins but resulted in aberrant localization pattern of Claudin-11⁺ junctions.
- Tracer dye assay testing AB integrity showed leakage of tracer into superficial cortex post-infection, supporting a GBS infection-induced AB breakdown.
- Upon infection, the morphology of BAMs was notably altered, from a small, round form to cells with processes as seen in activated macrophages.
- Although the overall density of BAMs did not differ, the number of CD206⁺/LYVE-1⁺ double-positive BAMs and the expression level of LYVE-1 was significantly decreased after infection.

ACKNOWLEDGMENTS

- Siegenthaler Lab (@SiegenthalerLab) | CU Anschutz
- Doran Lab (@KdoransLab) | CU Anschutz
- Cell Biology, Stem Cells, and Development (CSD) Program | CU Anschutz
- Funding support for this project from NIH/NINDS

FUTURE DIRECTIONS

- Investigate acute and chronic local immune response during meningeal barrier breakdown following neonatal GBS infection (a: pilot flow data on mock-injected animals).
 - Acute: immune cell response (neutrophils, infiltrating monocytes) and local cytokine production
 - Chronic: structural and functional integrity of AB and BAM profile after meningitis resolution
- Investigate the relevance and mechanism of LYVE-1 downregulation in BAMs during infection.
- Investigate the cellular and molecular mechanism underlying the mislocalization of Claudin-11 and potentially other AB junctional proteins (b: OB-cadherin, Type II cadherin expressed at AB cell junctions).

